Skip to main content
Top

15-09-2018 | Myositis | Review | Article

Current Treatment for Myositis

Journal: Current Treatment Options in Rheumatology

Authors: Simone Barsotti, MD, Ingrid E. Lundberg, MD, PhD

Publisher: Springer International Publishing

Abstract

Purpose of review

The purpose of this review was to give an update on treatment modalities for patients with idiopathic inflammatory myopathies, or shortly myositis, excluding the subgroup inclusion body myositis, based on a literature survey on therapies used in myositis. Few controlled trials have been performed in patients with myositis; therefore, we also included a summary of open-label trials, case series, and case reports.

Recent findings

Glucocorticoid (GC) in high doses is still the first-line treatment of patients with myositis. There is a general recommendation to combine GCs with another immunosuppressive agent in the early phase of disease to better control disease activity and possibly to reduce the risk for GC-related side effects. Furthermore, combining pharmacological treatment with individualized and supervised exercise can be recommended based on evidence. There is some evidence for the effect of rituximab in patients with certain myositis-specific autoantibodies, whereas other biologic agents are currently being tested in clinical trials.

Summary

Immunosuppressive treatment in combination with exercise is recommended for patients with myositis to reduce disease activity and improve muscle performance. Subgrouping of patients into clinical and serological subtypes may be a way to identify biomarkers for response to specific immunosuppressive and biological agents and should be considered in future trials.
Literature
1.
• Dalakas MC. Inflammatory muscle diseases. Longo DL, ed. N Engl J Med. 2015;372:1734–47. Comprehensive review about pathogenesis and clinical aspects of IIMs.CrossRef
2.
•• Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76:1955–64. New classification criteria for IIM proposed by an international task force.CrossRef
3.
Aggarwal R, Rider LG, Ruperto N, Bayat N, Erman B, Feldman BM, et al. 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an international myositis assessment and clinical studies group/Paediatric Rheu. Ann Rheum Dis. 2017;76:792–801.
4.
Oddis CV. Update on the pharmacological treatment of adult myositis. J Intern Med. 2016;280:63–74.CrossRef
5.
Lundberg I, Kratz AK, Alexanderson H, Patarroyo M. Decreased expression of interleukin-1alpha, interleukin-1beta, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis. Arthritis Rheum. 2000;43:336–48.
6.
Joffe MM, Love LA, Leff RL, Fraser DD, Targoff IN, Hicks JE, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med. 1993;94:379–87.
7.
Johnson NE, Arnold WD, Hebert D, Gwathmey K, Dimachkie MM, Barohn RJ, et al. Disease course and therapeutic approach in dermatomyositis: a four-center retrospective study of 100 patients. Neuromuscul Disord. 2015;25:625–31.
8.
Takada K, Kishi J, Miyasaka N. Step-up versus primary intensive approach to the treatment of interstitial pneumonia associated with dermatomyositis/polymyositis: a retrospective study. Mod Rheumatol. 2007;17:123–30.CrossRef
9.
Oddis CV, Medsger TA. Relationship between serum creatine kinase level and corticosteroid therapy in polymyositis-dermatomyositis. J Rheumatol. 1988;15:807–11.PubMed
10.
Cavagna L, Monti S, Caporali R, Gatto M, Iaccarino L, Doria A. How I treat idiopathic patients with inflammatory myopathies in the clinical practice. Autoimmun Rev. 2017;16:999–1007.
11.
Raghu P, Manadan AM, Schmukler J, Mathur T, Block JA. Pulse dose methylprednisolone therapy for adult idiopathic inflammatory myopathy. Am J Ther. 2015;22:244–7.
12.
Matsubara S, Hirai S, Sawa Y. Pulsed intravenous methylprednisolone therapy for inflammatory myopathies: evaluation of the effect by comparing two consecutive biopsies from the same muscle. J Neuroimmunol. 1997;76:75–80.CrossRef
13.
Iaccarino L, Bartoloni E, Gerli R, Alunno A, Barsotti S, Cafaro G, et al. Drugs in induction and treatment of idiopathic inflammatory myopathies. Auto Immun Highlights. 2014;5:95–100.
14.
van der Goes MC, Jacobs JWG, Boers M, Andrews T, Blom-Bakkers MAM, Buttgereit F, et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis. 2010;69:1913–9.
15.
Hoes JN, Jacobs JWG, Boers M, Boumpas D, Buttgereit F, Caeyers N, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007;66:1560–7.
16.
van de Vlekkert J, Hoogendijk JEE, de Haan RJJ, Algra A, van der Tweel I, van der Pol W, et al. Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial. Neuromuscul Disord. 2010;20:382–9.
17.
Mathur T, Manadan AM, Thiagarajan S, Hota B, Block JA. Corticosteroid monotherapy is usually insufficient treatment for idiopathic inflammatory myopathy. Am J Ther. 2015;22:350–4.
18.
Levine T. Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: a retrospective case series. Drug Des Devel Ther. 2012;6:133–9.CrossRef
19.•
Aggarwal R, Marder G, Koontz DC, Nandkumar P, Qi Z, Oddis CV. Efficacy and safety of adrenocorticotropic hormone gel in refractory dermatomyositis and polymyositis. Ann Rheum Dis. 2017; https://​doi.​org/​10.​1136/​annrheumdis-2017-212047. Open-label trial about ACTH gel in IIM patients demonstrating promising results.
20.
Woo TY, Callen JP, Voorhees JJ, Bickers DR, Hanno R, Hawkins C. Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol. 1984;10:592–600.
21.
Mittal L, Werth VP. The quinacrine experience in a population of patients with cutaneous lupus erythematosus and dermatomyositis. J Am Acad Dermatol. 2017;77:374–7.CrossRef
22.
Huber AM, Kim S, Reed AM, Carrasco R, Feldman BM, Hong SD, et al. Childhood arthritis and rheumatology research alliance consensus clinical treatment plans for juvenile dermatomyositis with persistent skin rash. J Rheumatol. 2017;44:110–6.
23.
Mittal L, Zhang L, Feng R, Werth VP. Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: a retrospective cohort study. J Am Acad Dermatol. 2018;78:100–106.e1.
24.
Marmor MF, Kellner U, Lai TYY, Melles RB, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016;123:1386–94.
25.
Mor A, Mitnick HJ, Pillinger MH, Wortmann RL. Drug-induced myopathies. Bull NYU Hosp Jt Dis. 2009;67:358–69.
26.
Pelle MT, Callen JP. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. Arch Dermatol. 2002;138:1231–3.PubMed
27.
Fendler C, Braun J. Use of methotrexate in inflammatory myopathies. Clin Exp Rheumatol. 2010;28:164–7.
28.
Miller J, Walsh Y, Saminanden S, Lecky B, Winer JB. Randomised double blind trial of methotrexate and steroids compared with azathioprine and steroids in the treatment of idiopathic inflammatory myopathy. J Neurol Sci. 2002;199:S53.
29.
Vencovský J, Jarosová K, Machácek S, et al. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol. 2000;29:95–102.CrossRef
30.
Villalba L, Hicks JE, Adams EM, Sherman JB, Gourley MF, Leff RL, et al. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum. 1998;41:392–9.
31.
Kasteler JS, Callen JP. Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis. J Am Acad Dermatol. 1997;36:67–71.CrossRef
32.
Hornung T, Ko A, Tüting T, Bieber T, Wenzel J. Efficacy of low-dose methotrexate in the treatment of dermatomyositis skin lesions. Clin Exp Dermatol. 2012;37(2):139–42.
33.
Click JW, Qureshi AA, Vleugels RA. Methotrexate for the treatment of cutaneous dermatomyositis. J Am Acad Dermatol. 2013;68:1043–5.CrossRef
34.
Combined treatment of methotrexate + glucocorticoids versus glucocorticoids alone in patients with PM and DM retrieved from https://​clinicaltrials.​gov/​ct2/​show/​NCT00651040
35.
Shea B, Swinden M V, Tanjong Ghogomu E, Ortiz Z, Katchamart W, Rader T, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. 2013;5:CD000951. https://​doi.​org/​10.​1002/​14651858.​CD000951.​pub2.
36.
U.S. Food and Drug Administration. Methotrexate safety information. 2011. Retrieved from http://​www.​accessdata.​fda.​gov/​drugsatfda_​docs/​label/​2011/​011719s117lbl.​pdf
37.
Kim Y-J, Song M, Ryu J-C. Mechanisms underlying methotrexate-induced pulmonary toxicity. Expert Opin Drug Saf. 2009;8:451–8.CrossRef
38.
Milone M. Diagnosis and management of immune-mediated myopathies. Mayo Clin Proc. 2017;92:826–37.CrossRef
39.
Bunch TW, Worthington JW, Combs JJ, Ilstrup DM, Engel AG. Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann Intern Med. 1980;92:365–9.
40.
Bunch TW. Prednisone and azathioprine for polymyositis: long-term follow-up. Arthritis Rheum. 1981;24:45–8.CrossRef
41.
Marie I, Hachulla E, Chérin P, Dominique S, Hatron PY, Hellot MF, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum. 2002;47:614–22.
42.
Tieu J, Lundberg IE, Limaye V. Idiopathic inflammatory myositis. Best Pract Res Clin Rheumatol. 2016;30:149–68.CrossRef
43.
Yu K-H, Wu Y-JJ, Kuo C-F, See LC, Shen YM, Chang HC, et al. Survival analysis of patients with dermatomyositis and polymyositis: analysis of 192 Chinese cases. Clin Rheumatol. 2011;30:1595–601.
44.
U.S. Food and Drug Administration. Azathioprine - product information. 2011. Retrieved from www.​accessdata.​fda.​gov/​drugsatfda_​docs/​label/​2011/​017391s015lbl.​pdf.
45.
Wan J, Imadojemu S, Werth VP. Management of rheumatic and autoimmune blistering disease in pregnancy and postpartum. Clin Dermatol. 2016;34:344–52.
46.
Ito M, Kaise S, Suzuki S, Kazuta Y, Sato Y, Miyata M, et al. Clinico-laboratory characteristics of patients with dermatomyositis accompanied by rapidly progressive interstitial lung disease. Clin Rheumatol. 1999;18:462–7.
47.
Kotani T, Takeuchi T, Makino S, Hata K, Yoshida S, Nagai K, et al. Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute/subacute interstitial pneumonia. Clin Rheumatol. 2011;30:1021–8.
48.
Oddis CV, Sciurba FC, Elmagd KA, Starzl TE. Tacrolimus in refractory poly myositis with inter stitial lung disease. Lancet. 1999;353:1762–3.
49.
Wilkes MR, Sereika SM, Fertig N, Lucas MR, Oddis CV. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum. 2005;52:2439–46.
50.
Witt LJ, Demchuk C, Curran JJ, Strek ME. Benefit of adjunctive tacrolimus in connective tissue disease-interstitial lung disease. Pulm Pharmacol Ther. 2016;36:46–52.
51.
Yokoyama Y, Furuta S, Ikeda K, Hirose K, Nakajima H. Corticosteroid-sparing effect of tacrolimus in the initial treatment of dermatomyositis and polymyositis. Mod Rheumatol. 2015;25:888–92.
52.
Cavagna L, Caporali R, Abdì-Alì L, Dore R, Meloni F, Montecucco C. Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease. J Rheumatol. 2013;40:484–92.
53.
Labirua-Iturburu A, Selva-O’Callaghan A, Martínez-Gómez X, et al. Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease. Clin Exp Rheumatol. 2013;31:436–9.PubMed
54.
U.S. Food and Drug Administration. Neoral - product information. 2009. Retrieved from https://​www.​accessdata.​fda.​gov/​drugsatfda_​docs/​label/​2009/​050715s027,050716s028lbl.​pdf.
55.
U.S. Food and Drug Administration. Tacrolimus - product information. 2009. Retrieved from https://​www.​accessdata.​fda.​gov/​drugsatfda_​docs/​label/​2009/​050708s027,050709s021lbl.​pdf.
56.
Pisoni CN, Cuadrado MJ, Khamashta MA, Hughes GRV, D’Cruz DP. Mycophenolate mofetil treatment in resistant myositis. Rheumatology (Oxford). 2007;46:516–8.
57.
Rowin J, Amato AA, Deisher N, Cursio J, Meriggioli MN. Mycophenolate mofetil in dermatomyositis: is it safe? Neurology. 2006;66:1245–7.
58.
Danieli MG, Calcabrini L, Calabrese V, Marchetti A, Logullo F, Gabrielli A. Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis. Autoimmun Rev. 2009;9:124–7.
59.
Edge JC, Outland JD, Dempsey JR, Callen JP. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol. 2006;142:65–9.
60.
Tsuchiya H, Tsuno H, Inoue M, Takahashi Y, Yamashita H, Kaneko H, et al. Mycophenolate mofetil therapy for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis. Mod Rheumatol. 2014;24:694–6.
61.
Saketkoo LA, Espinoza LR. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci. 2009;337:329–35.CrossRef
62.
Morganroth PA, Kreider ME, Werth VP. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res. 2010;62:1496–501.CrossRef
63.
Yamasaki Y, Yamada H, Yamasaki M, Ohkubo M, Azuma K, Matsuoka S, et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford). 2007;46:124–30.
64.
Bombardieri S, Hughes GRV, Neri R, Del Bravo P, Del Bono L. Cyclophosphamide in severe polymyositis. Lancet. 1989;333:1138–9.
65.
Ge Y, Peng Q, Zhang S, Zhou H, Lu X, Wang G. Cyclophosphamide treatment for idiopathic inflammatory myopathies and related interstitial lung disease: a systematic review. Clin Rheumatol. 2015;34:99–105.
66.
Shinohara T, Hidaka T, Matsuki Y, et al. Rapidly progressive interstitial lung disease associated with dermatomyositis responding to intravenous cyclophosphamide pulse therapy. Intern Med. 1997;36:519–23.CrossRef
67.
Kameda H, Nagasawa H, Ogawa H, Sekiguchi N, Takei H, Tokuhira M, et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol. 2005;32:1719–26.
68.
Hisanaga J, Kotani T, Fujiki Y, Yoshida S, Takeuchi T, Makino S. Successful multi-target therapy including rituximab and mycophenolate mofetil in anti-melanoma differentiation-associated gene 5 antibody-positive rapidly progressive interstitial lung disease with clinically amyopathic dermatomyositis. Int J Rheum Dis. 2017;20:2182–5.
69.
Mira-Avendano IC, Parambil JG, Yadav R, Arrossi V, Xu M, Chapman JT, et al. A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis/dermatomyositis. Respir Med. 2013;107:890–6.
70.
Notarnicola A, Dastmalchi M, Nyren S, Gunnarsson K, Dani L, Lundberg I. SAT0329 intravenous cyclophosphamide according to the euro-lupus nephritis protocol for progressive interstitial lung disease in patients with polymyositis/dermatomyositis. Ann Rheum Dis. 2017;76:896.2–896.
71.
U.S. Food and Drug Administration. Cyclophosphamide - product information. 2013. Retrieved from https://​www.​accessdata.​fda.​gov/​drugsatfda_​docs/​label/​2013/​012141s090,012142s112lbl.​pdf.
72.
Lünemann JD, Quast I, Dalakas MC, Lunemann JD, Quast I, Dalakas MC. Efficacy of intravenous immunoglobulin in neurological diseases. Neurotherapeutics. 2016;13:34–46.
73.
Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. NEJM. 1993;329:1993–2000.CrossRef
74.
Miyasaka N, Hara M, Koike T, Saito E, Yamada M, Tanaka Y, et al. Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial. Mod Rheumatol. 2012;22:382–93.
75.
Cherin P, Pelletier S, Teixeira A, Laforet P, Genereau T, Simon A, et al. Results and long-term follow-up of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum. 2002;46:467–74.
76.
Saito E, Koike T, Hashimoto H, Miyasaka N, Ikeda Y, Hara M, et al. Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and dermatomyositis. Mod Rheumatol. 2008;18:34–44.
77.
Femia AN, Vleugels RA, Callen JP. Cutaneous dermatomyositis: an updated review of treatment options and internal associations. Am J Clin Dermatol. 2013;1:291–313.CrossRef
78.
Bakewell CJ, Raghu G. Polymyositis associated with severe interstitial lung disease: remission after three doses of IV immunoglobulin. Chest. 2011;139:441–3.CrossRef
79.
Suzuki Y, Hayakawa H, Miwa S, Shirai M, Fujii M, Gemma H, et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung. 2009;187:201–6.
80.
Marie I, Menard J-F, Hatron PY, et al. Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients. Arthritis Care Res. 2010;62:1748–55.CrossRef
81.
Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology. 2001;56:323–7.
82.
Cherin P, Delain J-C, de Jaeger C, Crave J-C. Subcutaneous immunoglobulin use in inclusion body myositis: a review of 6 cases. Case Rep Neurol. 2015;7:227–32.
83.
•• Anh-Tu Hoa S, Hudson M. Critical review of the role of intravenous immunoglobulins in idiopathic inflammatory myopathies. Semin Arthritis Rheum. 2017;46:488–508. Comprehensive review about IvIg in IIM.CrossRef
84.
Barbasso Helmers S, Dastmalchi M, Alexanderson H, et al. Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies. Ann Rheum Dis. 2007;66:1276–83.CrossRef
85.
• Mammen AL, Tiniakou E. Intravenous immune globulin for statin-triggered autoimmune myopathy. N Engl J Med. 2015;373:1680–2. Promising results of the use of IvIg as first-line treatment in a well-defined subgroup of IIM with HMGCR antibodies.CrossRef
86.
Imbach P, Barandun S, d’Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;1:1228–31.
87.
Danieli MG, Malcangi G, Palmieri C, Logullo F, Salvi A, Piani M, et al. Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis. 2002;61:37–41.
88.
Gelardi C, Paolini L, Danieli MG. Subcutaneous immunoglobulin G in idiopathic inflammatory myopathies: therapeutic implications. IMAJ. 2014;16:1.
89.•
Hachulla E, Benveniste O, Hamidou M, et al. High dose subcutaneous immunoglobulin for idiopathic inflammatory myopathies and dysimmune peripheral chronic neuropathies treatment: observational study of quality of life and tolerance. Int J Neurosci. 2017;127:516–23. Open-label trial on treatment of IIM with subcutaneous immunoglobulins.
90.
Neri R, Barsotti S, Iacopetti V, et al. Cancer-associated myositis: a 35-year retrospective study of a monocentric cohort. Rheumatol Int. 2014;34:565–9.CrossRef
91.
Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 2005;52:601–7.CrossRef
92.
Mok CC, Ho LY, To CH. Rituximab for refractory polymyositis: an open-label prospective study. J Rheumatol. 2007;34:1864–8.PubMed
93.
Couderc M, Gottenberg J-E, Mariette X, Hachulla E, Sibilia J, Fain O, et al. Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry. Rheumatology. 2011;50:2283–9.
94.
Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65:314–24.
95.
Fasano S, Gordon P, Hajji R, Loyo E, Isenberg DA. Rituximab in the treatment of inflammatory myopathies: a review. Rheumatology. 2017;56:26–36.
96.
Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol. 2014;66:740–9.
97.
Allenbach Y, Guiguet M, Rigolet A, Marie I, Hachulla E, Drouot L, et al. Efficacy of rituximab in refractory inflammatory myopathies associated with anti-synthetase auto-antibodies: an open-label, Phase II Trial. PLoS One. 2015;10:e0133702.
98.
• Svensson J, Holmqvist M, Tjarnlund A, et al. Use of biologic agents in idiopathic inflammatory myopathies in Sweden: a descriptive study of real life treatment. Clin Exp Rheumatol. 2017;35(3):512–5. Overview of real-life experience of the use of biologic agents in IIM in a national wide cohort.PubMed
99.
Andersson H, Sem M, Lund MB, et al. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology (United Kingdom). 2015;54:1420–8.
100.•
Aggarwal R, Loganathan P, Koontz D, Qi Z, Reed AM, Oddis CV. Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. Rheumatology (Oxford). 2016;56:247–54. Interesting study about the efficacy of rituximab for the treatment of skin rash in IIM patients.
101.
Valiyil R, Casciola-Rosen L, Hong G, Mammen A, Christopher-Stine L. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res. 2010;62:1328–34.
102.
Aggarwal R, Oddis CV, Goudeau D, et al. Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab. Rheumatology (Oxford). 2016;55:991–9.CrossRef
103.
104.
Van Assen S, Elkayam O, Cervera R, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011;70:414–22.CrossRef
105.
Kerola AM, Kauppi MJ. Abatacept as a successful therapy for myositis—a case-based review. Clin Rheumatol. 2015;34:609–12.CrossRef
106.
•• Tjärnlund A, Tang Q, Wick C, et al. Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial. Ann Rheum Dis. 2018;77:55–62. An open randomized trial with delayed start design suggesting efficacy of intravenous abatacept treatment in a subgroup of patients with refractory IIM.CrossRef
107.
Barsotti S, Bruni C, Cometi L, et al. One year in review 2017: idiopathic inflammatory myopathies. Clin Exp Rheumatol. 2017;35:0875–84.
108.
Muscle Study Group TMS. A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol. 2011;70:427–36.CrossRef
109.
Iannone F, Scioscia C, Falappone PCF, Covelli M, Lapadula G. Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol. 2006;33:1802–4.
110.
• Schiffenbauer A, Garg M, Castro C, et al. A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis. Semin Arthritis Rheum. 2017;47:858–64. Recent report about the use of infliximab in IIMs, showing a good tolerability of the treatment and the possible efficacy in a subset of IIM patients.CrossRef
111.
Dastmalchi M, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Helmers SB, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis. 2008;67:1670–7.
112.
Hengstman GJD, De Bleecker JL, Feist E, et al. Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol. 2008;59:159–63.CrossRef
113.
Dicaro D, Bowen C, Dalton SR. Dermatomyositis associated with anti-tumor necrosis factor therapy in a patient with psoriasis. J Am Acad Dermatol. 2014;70:e64–5.CrossRef
114.
Nagashima T, Minota S. Dermatomyositis in patients with rheumatoid arthritis during adalimumab therapy. J Rheumatol. 2011;38:574.CrossRef
115.
Narazaki M, Hagihara K, Shima Y, Ogata A, Kishimoto T, Tanaka T. Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology. 2011;50:1344–6.
116.
Kondo M, Murakawa Y, Matsumura T, Matsumoto O, Taira M, Moriyama M, et al. A case of overlap syndrome successfully treated with tocilizumab: a hopeful treatment strategy for refractory dermatomyositis? Rheumatology. 2014;53:1907–8.
117.
Kosmidis ML, Alexopoulos H, Tzioufas AG, Dalakas MC. The effect of anakinra, an {IL}1 receptor antagonist, in patients with sporadic inclusion body myositis ({sIBM}): a small pilot study. J Neurol Sci. 2013;334:123–5.
118.
Zong M, Dorph C, Dastmalchi M, et al. Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up. Ann Rheum Dis. 2013;73:913–20.CrossRef
119.
Dalakas MC, Rakocevic G, Schmidt J, Salajegheh M, McElroy B, Harris-Love MO, et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain J Neurol. 2009;132:1536–44.
120.
Ruck T, Bittner S, Kuhlmann T, Wiendl H, Meuth SG. Long-term efficacy of alemtuzumab in polymyositis. Rheumatology (Oxford). 2015;54:560–2.
121.
Higgs BW, Zhu W, Morehouse C, White WI, Brohawn P, Guo X, et al. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis. 2014;73:256–62.
122.
Zou J, Li T, Huang X, Chen S, Guo Q, Bao C. Basiliximab may improve the survival rate of rapidly progressive interstitial pneumonia in patients with clinically amyopathic dermatomyositis with anti-MDA5 antibody. Ann Rheum Dis. 2014;73:1591–3.
123.
Study of tofacitinib in refractory dermatomyositis (STIR). 22/08/2018. Retrieved from https://​clinicaltrials.​gov/​ct2/​show/​NCT03002649
124.
Dau PC. Plasmapheresis in idiopathic inflammatory myopathy. Experience with 35 patients. Arch Neurol. 1981;38:544–52.CrossRef
125.
Miller FW, Leitman SF, Cronin ME, Hicks JE, Leff RL, Wesley R, et al. Controlled trial of plasma exchange and Leukapheresis in polymyositis and dermatomyositis. N Engl J Med. 1992;326:1380–4.
126.
Schwartz J, Padmanabhan A, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing Committee of the American Society for apheresis: the seventh special issue. J Clin Apher. 2016;31:149–338.PubMed
127.
Selva-O’callaghan A, Vizcaino C, Ruiz-Rodriguez J, et al. Anti-mda5 (+) clinically amyopathic dermatomyositis-associated rapidly progressive interstitial lung disease: role of hemoperfusion with polymyxin. Ann Rheum Dis. 2018;77:A1095.
128.
Ichiyasu H, Sakamoto Y, Yoshida C, et al. Rapidly progressive interstitial lung disease due to anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis complicated with cervical cancer: successful treatment with direct hemoperfusion using polymyxin B-immobilized fiber column therapy. Respir Med Case Rep. 2017;20:51–4.PubMed
129.
Bertolucci F, Neri R, Dalise S, Venturi M, Rossi B, Chisari C. Abnormal lactate levels in patients with polymyositis and dermatomyositis: the benefits of a specific rehabilitative program. Eur J Phys Rehabil Med. 2014;50:161–9.
130.
Alemo Munters L, Dastmalchi M, Andgren V, et al. Improvement in health and possible reduction in disease activity using endurance exercise in patients with established polymyositis and dermatomyositis: a multicenter randomized controlled trial with a 1-year open extension follow-up. Arthritis Care Res (Hoboken). 2013;65:1959–68.CrossRef
131.
Varjú C, Pethö E, Kutas R, Czirják L, Varju C. Petho, Edit. Kutas R. The effect of physical exercise following acute disease exacerbation in patients with dermato/polymyositis. Clin Rehabil. 2003;17:83–7.
132.
Alexanderson H, Munters LA, Dastmalchi M, Loell I, Heimburger M, Opava CH, et al. Resistive home exercise in patients with recent-onset polymyositis and dermatomyositis - a randomized controlled single-blinded study with a 2-year follow-up. J Rheumatol. 2014;41:1124–32.
133.
• Alexanderson H, Regardt M, Ottosson C, et al. Muscle strength and muscle endurance during the first year of treatment of polymyositis and dermatomyositis: a prospective study. J Rheumatol. 2018;45:538–46. A randomized open study showing long-term effects and safety of early introduction of physical training in combination with immunosuppressive treatment of IIM.CrossRef
134.
Alexanderson H, Dastmalchi M, Esbjörnsson-Liljedahl M, Opava CH, Lundberg IE. Benefits of intensive resistance training in patients with chronic polymyositis or dermatomyositis. Arthritis Rheum. 2007;57:768–77.
135.
Alexanderson H. Physical exercise as a treatment for adult and juvenile myositis. J Intern Med. 2016;280:75–96.CrossRef
136.
Lundberg IE, Vencovsky J, Alexanderson H. Therapy of myositis. Curr Opin Rheumatol. 2014;26:704–11.
137.
Tiffreau V, Rannou F, Kopciuch F, Hachulla E, Mouthon L, Thoumie P, et al. Postrehabilitation functional improvements in patients with inflammatory myopathies: the results of a randomized controlled trial. Arch Phys Med Rehabil. 2017;98:227–34.
138.
Arnardottir S, Alexanderson H, Lundberg IE, Borg K. Sporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction. J Rehabil Med. 2003;35:31–5.
139.
Chung YL, Alexanderson H, Pipitone N, Morrison C, Dastmalchi M, Ståhl-Hallengren C, et al. Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: six-month, double-blind, randomized, placebo-controlled trial. Arthritis Care Res. 2007;57:694–702.
140.
Solis MY, Hayashi AP, Artioli GG, Roschel H, Sapienza MT, Otaduy MC, et al. Efficacy and safety of creatine supplementation in juvenile dermatomyositis: a randomized, double-blind, placebo-controlled crossover trial. Muscle Nerve. 2016;53:58–66.
141.
Kley RA, Tarnopolsky MA, Vorgerd M. Creatine for treating muscle disorders. Cochrane Database Syst Rev. 2013;(6):CD004760. https://​doi.​org/​10.​1002/​14651858.​CD004760.​pub4.